ReviewNutrients2013
Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches.
Review in Nutrients, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 160 citations in OpenAlex.
- Combined effect of plant sterols and dietary fiber for the treatment of hypercholesterolemia.Plant foods for human nutrition (Dordrecht, Netherlands) · 2014Pooled it
- Effects of Weight Loss and Weight Maintenance on Lipoprotein Insulin Resistance Scores in Adults with Overweight and Obesity.Metabolic syndrome and related disorders · 2024Trial
- Diverging metabolic effects of 2 energy-restricted diets differing in nutrient quality: a 12-week randomized controlled trial in subjects with abdominal obesity.The American journal of clinical nutrition · 2022Trial
- Effects of 12-week supplementation of Citrus bergamia extracts-based formulation CitriCholess on cholesterol and body weight in older adults with dyslipidemia: a randomized, double-blind, placebo-controlled trial.Lipids in health and disease · 2017Trial
- Comprehensive Analysis of Established Dyslipidemia-Associated Loci in the Diabetes Prevention Program.Circulation. Cardiovascular genetics · 2016Trial
- Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.Hepatology (Baltimore, Md.) · 2015Trial
- Freeze-dried strawberries lower serum cholesterol and lipid peroxidation in adults with abdominal adiposity and elevated serum lipids.The Journal of nutrition · 2014Trial
- Trial
- Biomarkers in Obesity-Related Metabolic Syndrome: Relationships Between LDL Subfractions, Lipid Profile, and Cardiometabolic Risk in a Slovak Population.Metabolites · 2026Article
- Correlation Between Small Dense Low-Density Lipoprotein and Tissue Perfusion in Diabetic Foot.Journal of Korean medical science · 2026Article
- Serum small dense LDL cholesterol is inversely associated with kidney stone prevalence: evidence from two independent cross-sectional studies.Frontiers in endocrinology · 2026Article
- Association between Remnant Cholesterol and Metabolic Syndrome beyond Conventional Lipid Parameters in Middle Age and Elderly Population: Bushehr Elderly Health (BEH) cohort.Journal of diabetes and metabolic disorders · 2025Article
- Examining the interplay between sdLDL, resistin, and BMI.Scientific reports · 2025Article
- S-shaped association between hs-CRP/HDL-C index and overweight/obesity in children and adolescents: a population-based study.European journal of medical research · 2025Article
- The Effect of Theobromine Supplementation on HDL-c Subclasses (HDL-c2, HDL-c3), HDL-c2/HDL-c3 Ratio, and Gene Expression of PPAR-α and Sirt1 in Subjects With Metabolic Syndrome: A Randomized Controlled Clinical Trial.Food science & nutrition · 2025Article
- Relationship of small dense low-density lipoprotein cholesterol level with pre-diabetes and newly detected type 2 diabetes.Scientific reports · 2025Article
- Therapeutic Potential of Cranberry Proanthocyanidins in Addressing the Pathophysiology of Metabolic Syndrome: A Scrutiny of Select Mechanisms of Action.Antioxidants (Basel, Switzerland) · 2025Article
- Association between visceral fat area and metabolic syndrome in individuals with normal body weight: insights from a Chinese health screening dataset.Lipids in health and disease · 2025Article
- Analysis of TEM micrographs with deep learning reveals APOE genotype-specific associations between HDL particle diameter and Alzheimer's dementia.Cell reports methods · 2025Article
- Relative increase in production ratio of small dense low-density lipoprotein in acute coronary syndrome with high coronary plaque burden: an ex-vivo analysis.Heart and vessels · 2025Observational
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small, dense low density lipoprotein (sdLDL) represents an emerging cardiovascular risk factor, since these particles can be associated with cardiovascular disease (CVD) independently of established risk factors, including plasma lipids. Obese subjects frequently have atherogenic dyslipidaemia, including elevated sdLDL levels, in addition to elevated triglycerides (TG), very low density lipoprotein (VLDL) and apolipoprotein-B, as well as decreased high density lipoprotein cholesterol (HDL-C) levels. Obesity-related co-morbidities, such as metabolic syndrome (MetS) are also characterized by dyslipidaemia. Therefore, agents that favourably modulate LDL subclasses may be of clinical value in these subjects. Statins are the lipid-lowering drug of choice. Also, anti-obesity and lipid lowering drugs other than statins could be useful in these patients. However, the effects of anti-obesity drugs on CVD risk factors remain unclear. We review the clinical significance of sdLDL in being overweight and obesity, as well as the efficacy of anti-obesity drugs on LDL subfractions in these individuals; a short comment on HDL subclasses is also included. Our literature search was based on PubMed and Scopus listings. Further research is required to fully explore both the significance of sdLDL and the efficacy of anti-obesity drugs on LDL subfractions in being overweight, obesity and MetS. Improving the lipoprotein profile in these patients may represent an efficient approach for reducing cardiovascular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.